Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for AMG.DE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AMG.DE and 80,000+ other tickers.
See exactly how AMG.DE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AMG.DE and 80,000+ other tickers.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, operates globally as a biopharmaceutical company focused on discovering, developing, manufacturing, and delivering human therapeutics. The firm concentrates its research and development efforts on critical therapeutic areas such as inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Its extensive product portfolio includes a range of impactful medicines. Examples feature Enbrel for autoimmune conditions like psoriasis and arthritis, Neulasta to mitigate infection…
No recent news available.